ArticleFrontiers in immunology2026
Urinary miR-142-3p: a novel biomarker of the progression of IgA nephropathy.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The prognosis of IgA nephropathy (IgAN) varies greatly but tends to be poor. The purpose of the present study was to screen for urinary sediment miRNAs that could be used for the non-invasive prediction of IgAN progression and to explore the mechanisms explaining this. Methods: We studied two independent cohorts (2014-2015 and 2018-2022) to identify urinary sediment miRNAs that could be used to predict IgAN progression. Bioinformatic analysis and dual-luciferase experiments were used to identify target genes for miR-142-3p. The fibrotic phenotype of tubular epithelial cells was evaluated in HK-2 cells. Results: In both the training and validation cohorts, the urinary miR-142-3p expression in patients who showed IgAN progression was significantly higher than that in those who did not ( Conclusions: Urinary miR-142-3p is a biomarker for the progression of IgAN and is involved in the exacerbation of renal fibrosis. Urinary miR-142-3p can be used to replace pathologic indices in the IIGANPT without reducing its predictive efficacy, implying that this modified tool could be used to non-invasively predict IgAN progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.